TR200102012T2 - Yumurtalık kanserinin tedavi yöntemleri, poli (fosfoester) bileşimler ile bunlara ait biyolojik olarak parçalanabilir maddeler. - Google Patents

Yumurtalık kanserinin tedavi yöntemleri, poli (fosfoester) bileşimler ile bunlara ait biyolojik olarak parçalanabilir maddeler.

Info

Publication number
TR200102012T2
TR200102012T2 TR2001/02012T TR200102012T TR200102012T2 TR 200102012 T2 TR200102012 T2 TR 200102012T2 TR 2001/02012 T TR2001/02012 T TR 2001/02012T TR 200102012 T TR200102012 T TR 200102012T TR 200102012 T2 TR200102012 T2 TR 200102012T2
Authority
TR
Turkey
Prior art keywords
experiment
phosphoester
ovarian cancer
antineoplastic agent
poly
Prior art date
Application number
TR2001/02012T
Other languages
English (en)
Inventor
Dang Wenbin
Original Assignee
Guilford Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilford Pharmaceuticals Inc. filed Critical Guilford Pharmaceuticals Inc.
Publication of TR200102012T2 publication Critical patent/TR200102012T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/908—Mechanical repair performed/surgical
    • Y10S977/911—Cancer cell destruction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/908—Mechanical repair performed/surgical
    • Y10S977/912—Cancer cell repair

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Yumurtalik kanseri memeli deneyin tedavisinde pertion içine verilmeye elverisli biyolojik olarak parçalanabilir polimer bilesimleri açiklanmaktadir. Bilesim (a) en azindan bir antineoplastik ajan ile (b) biyolojik olarak parçalanabilir bir fosfoester polimeri ihtiva eder. Burada polimer bilesimi antineoplastik ajanin deneyin peritonu içine uzatilmis süre ile verilebilmesini saglar. Deneye antineoplastik ajanla birlikte verilen polimer bilesimi, ayni dozaja sahip ancak bulusa konu biyolojik olarak parçalanabilir polimer olmaksizin deneye verilen antineoplastik ajanin sagladigi hayatta kalma oranini en azindan %10 arttirmaktadir. Yumurtalik kanserinin tedavisiyle ilgili kati madde ve yöntemler de tariflenmektedir.
TR2001/02012T 1999-01-11 1999-12-23 Yumurtalık kanserinin tedavi yöntemleri, poli (fosfoester) bileşimler ile bunlara ait biyolojik olarak parçalanabilir maddeler. TR200102012T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/227,852 US6350464B1 (en) 1999-01-11 1999-01-11 Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same

Publications (1)

Publication Number Publication Date
TR200102012T2 true TR200102012T2 (tr) 2002-01-21

Family

ID=22854735

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02012T TR200102012T2 (tr) 1999-01-11 1999-12-23 Yumurtalık kanserinin tedavi yöntemleri, poli (fosfoester) bileşimler ile bunlara ait biyolojik olarak parçalanabilir maddeler.

Country Status (20)

Country Link
US (4) US6350464B1 (tr)
EP (1) EP1140028B1 (tr)
JP (1) JP2002534456A (tr)
KR (1) KR20010101472A (tr)
CN (1) CN1337878A (tr)
AT (1) ATE310506T1 (tr)
AU (1) AU779182B2 (tr)
BR (1) BR9916881A (tr)
CA (1) CA2359109C (tr)
CZ (1) CZ20012416A3 (tr)
DE (1) DE69928567T2 (tr)
HU (1) HUP0202670A3 (tr)
IL (2) IL145087A0 (tr)
IN (1) IN2001CH01053A (tr)
MX (1) MX236541B (tr)
NO (1) NO20013402L (tr)
RU (1) RU2001122708A (tr)
TR (1) TR200102012T2 (tr)
WO (1) WO2000041678A1 (tr)
ZA (1) ZA200106499B (tr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548302B1 (en) 1998-06-18 2003-04-15 Johns Hopkins University School Of Medicine Polymers for delivery of nucleic acids
US6537585B1 (en) 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
AU6536400A (en) * 1999-08-11 2001-03-05 Alkermes Controlled Therapeutics, Inc. Method of delivering a chemotherapeutic agent to a solid tumor
US20020041897A1 (en) * 2000-07-07 2002-04-11 Wenbin Dang Compositions for sustained release of antineoplastic taxanes, and methods of making and using the same
US20020045668A1 (en) * 2000-07-17 2002-04-18 Wenbin Dang Compositions for sustained release of analgesic agents, and methods of making and using the same
WO2002028372A2 (en) * 2000-10-06 2002-04-11 Johns Hopkins University Systemic delivery of compounds through non-invasive bladder administration
AU2002215333A1 (en) * 2000-10-12 2002-04-22 Guilford Pharmaceuticals Inc. Compositions for release of radiosensitizers, and methods of making and using the same
US20020141966A1 (en) * 2000-11-16 2002-10-03 Wenbin Dang Compositions for treatment of malignant effusions, and methods of making and using the same
US20030133903A1 (en) * 2001-07-19 2003-07-17 Wenbin Dang Compositions for treatment of prostate cancers and methods of making and using the same
WO2003007915A2 (en) * 2001-07-19 2003-01-30 Guilford Pharmaceuticals, Inc. Compositions for treatment of head and neck cancers, and methods of making and using the same
WO2003060799A2 (en) * 2002-01-09 2003-07-24 Guilford Pharmaceuticals, Inc. Compositions for treatment of central nervous system neoplasms, and methods of making and using the same
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
US20050244402A1 (en) * 2004-04-30 2005-11-03 Villanueva Julie M Absorption of pain-causing agents
WO2006002365A2 (en) * 2004-06-24 2006-01-05 Angiotech International Ag Microparticles with high loadings of a bioactive agent
US7871573B2 (en) * 2004-07-26 2011-01-18 University Of Louisville Research Foundation, Inc. Enhancement of sensitivity of fluorophore mediated biosensing and bioimaging
US8563328B2 (en) * 2004-07-26 2013-10-22 University Of Louisville Research Foundation, Inc. Fiber-optic biosensor and biosensing methods
US7517914B2 (en) * 2005-04-04 2009-04-14 Boston Scientificscimed, Inc. Controlled degradation materials for therapeutic agent delivery
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
GB0525864D0 (en) * 2005-12-20 2006-02-01 Novartis Ag Organic compounds
EP3009477B1 (en) 2006-07-20 2024-01-24 Orbusneich Medical Pte. Ltd Bioabsorbable polymeric composition for a medical device
US20090169628A1 (en) * 2006-10-17 2009-07-02 Armark Authentication Technologies, Llc Article and method for focused delivery of therapeutic and/or diagnostic materials
US7959942B2 (en) 2006-10-20 2011-06-14 Orbusneich Medical, Inc. Bioabsorbable medical device with coating
US8691321B2 (en) 2006-10-20 2014-04-08 Orbusneich Medical, Inc. Bioabsorbable polymeric composition and medical device background
WO2009085952A1 (en) 2007-12-20 2009-07-09 Brookwood Pharmaceuticals, Inc. Process for preparing microparticles having a low residual solvent volume
WO2009088777A1 (en) * 2007-12-31 2009-07-16 Armark Authentication Technologies, Llc Article and method for focused delivery of therapeutic and/or diagnostic materials
US20100078848A1 (en) * 2008-09-29 2010-04-01 Armark Authentication Technologies, Llc Spinneret and method of spinning fiber
US20100291214A1 (en) * 2008-12-23 2010-11-18 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
US20100291384A1 (en) * 2009-05-15 2010-11-18 Armark Authentication Technologies, Llc Fiber having non-uniform composition and method for making same
CN103917224A (zh) * 2011-07-19 2014-07-09 Stc·Unm公司 基于在癌症的炎症环境释放治疗性负载的腹膜内给药的纳米载体
WO2013170069A1 (en) 2012-05-09 2013-11-14 Massachusetts Institute Of Technology Medicament, method, and drug delivery device for treatment of ovarian cancer

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA597473A (en) 1960-05-03 Starck Werner Process for the manufacture of phosphorus-containing polyesters and copolymers thereof
US2891915A (en) 1954-07-02 1959-06-23 Du Pont Organophosphorus polymers
US3271329A (en) 1958-09-19 1966-09-06 Eastman Kodak Co Method for producing polymers derived from phosphites and glycols
US3442982A (en) 1965-10-15 1969-05-06 Weston Chemical Corp Polyphosphites of 2,2-dimethyl-3-hydroxypropyl - 2 - dimethyl - 3-hydroxypropionate
FR2219193B1 (tr) 1973-02-28 1976-05-21 Rhone Poulenc Sa
US3932566A (en) 1974-09-16 1976-01-13 Celanese Corporation Phosphonate polymers
US4100354A (en) 1976-08-05 1978-07-11 Owens-Corning Fiberglass Corporation Terephthalate ester polyols
US4259222A (en) 1978-08-16 1981-03-31 Basf Wyandotte Corporation Linear saturated polyesters of phosphoric acid and halogenated diols as flame-retardant additives and coatings
DE2925206A1 (de) 1979-06-22 1981-01-29 Bayer Ag Aromatische polyesterphosphonate, verfahren zu ihrer herstellung und ihre verwendung zur herstellung thermoplastischer formkoerper
FR2498612A1 (fr) 1981-01-26 1982-07-30 Peters Ligatures Nouveaux polymeres insolubles a biodegradabilite reglable a volonte, leurs procedes de preparation et leur application en tant que biomateriaux
US4757128A (en) 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
US4474937A (en) 1983-10-03 1984-10-02 The Dow Chemical Company Phosphorus-modified polyestercarbonate resins
US4481353A (en) 1983-10-07 1984-11-06 The Children's Medical Center Corporation Bioresorbable polyesters and polyester composites
US4746462A (en) 1985-02-21 1988-05-24 Dainichiseika Color & Chemicals Mfg. Co., Ltd. Phosphoric ester compound
US4789724A (en) 1986-10-17 1988-12-06 Massachusetts Institute Of Technology Preparation of anhydride copolymers
US4978332A (en) 1987-09-28 1990-12-18 Matrix Pharmaceutical, Inc. Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas
US5256765A (en) 1989-03-09 1993-10-26 The Johns Hopkins University School Of Medicine Biodegradable poly(phosphate esters)
US5194581A (en) 1989-03-09 1993-03-16 Leong Kam W Biodegradable poly(phosphoesters)
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
NZ240214A (en) 1990-10-16 1993-02-25 Takeda Chemical Industries Ltd Polymer compositions comprising a polylactic acid and a copolymer of glycolic acid and a hydroxycarboxylic acid; use as carrier for prolonged release pharmaceutical compositions of water soluble drugs
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
AU681231B2 (en) 1993-12-29 1997-08-21 Intarcia Therapeutics, Inc. Methods and compositions for the treatment of a host with a cellular proliferative disease
DE4404365A1 (de) 1994-02-11 1995-08-17 Cassella Ag Phosphin- und phosphonsäuregruppenhaltige Polykondensate
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
WO1996022786A1 (en) 1995-01-23 1996-08-01 Takeda Chemical Industries, Ltd. Sustained-release preparation and use
US5637085A (en) 1995-11-20 1997-06-10 Cardinale; Robert M. Method of cancer tumor treatment by slow release delivery of 1,2,4-benzotriazine oxides to tumor site
EP0895517B1 (en) 1996-04-23 2004-11-17 Ipsen Manufacturing Ireland Limited Acidic polylactic polymers
US5993856A (en) 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
US6334445B1 (en) 1997-03-27 2002-01-01 Baker Norton Pharmaceuticals, Inc. Methods and compositions for treatment of ovarian cancer
UA54505C2 (uk) 1997-04-03 2003-03-17 Гілфорд Фармасьютікалз Інк. Полімери, що біологічно розкладаються, зшиті фосфатами, композиції, вироби і способи для їх виготовлення і використання
US6322797B1 (en) 1997-04-03 2001-11-27 Guilford Pharmaceuticals, Inc. Biodegradable terephthalate polyester-poly (phosphate) polymers, compositions, articles, and methods for making and using the same
US5912225A (en) 1997-04-14 1999-06-15 Johns Hopkins Univ. School Of Medicine Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same
WO1998048859A1 (en) 1997-04-30 1998-11-05 Guilford Pharmaceuticals Inc. Biodegradable compositions comprising poly(cycloaliphatic phosphoester) compounds, articles, and methods for using the same
CA2295209A1 (en) 1997-06-18 1998-12-23 Zhong Zhao Two-stage solution polymerization of high molecular weight poly(phosphoesters)
US6028163A (en) 1997-06-27 2000-02-22 Guilford Pharmaceuticals Inc. Solution polymerization of high molecular weight poly(phosphoesters) in toluene
JP2002526396A (ja) 1998-10-02 2002-08-20 ギルフォード ファーマシュウティカルズ インコーポレイテッド 生分解性テレフタレートポリエステル−ポリホスホネートとポリエステル−ポリホスファイトの組成物、物品、及びそれらの使用方法
US6419709B1 (en) 1998-10-02 2002-07-16 Guilford Pharmaceuticals, Inc. Biodegradable terephthalate polyester-poly(Phosphite) compositions, articles, and methods of using the same
US6153212A (en) * 1998-10-02 2000-11-28 Guilford Pharmaceuticals Inc. Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
AU777528B2 (en) 1999-04-22 2004-10-21 Abraxis Bioscience, Llc Long term administration of pharmacologically active agents

Also Published As

Publication number Publication date
DE69928567T2 (de) 2006-08-17
IL144087A0 (en) 2002-05-23
IL145087A0 (en) 2002-06-30
HUP0202670A2 (hu) 2002-11-28
BR9916881A (pt) 2002-05-07
HUP0202670A3 (en) 2003-02-28
DE69928567D1 (de) 2005-12-29
MX236541B (es) 2006-05-04
CZ20012416A3 (cs) 2001-11-14
NO20013402D0 (no) 2001-07-09
CN1337878A (zh) 2002-02-27
NO20013402L (no) 2001-09-11
EP1140028A1 (en) 2001-10-10
ATE310506T1 (de) 2005-12-15
US6350464B1 (en) 2002-02-26
US20010038849A1 (en) 2001-11-08
AU2059100A (en) 2000-08-01
CA2359109C (en) 2011-02-22
US6641833B2 (en) 2003-11-04
MXPA01007018A (es) 2005-07-01
EP1140028B1 (en) 2005-11-23
RU2001122708A (ru) 2004-02-20
ZA200106499B (en) 2002-11-07
WO2000041678A1 (en) 2000-07-20
IN2001CH01053A (en) 2005-03-04
CA2359109A1 (en) 2000-07-20
AU779182B2 (en) 2005-01-13
KR20010101472A (ko) 2001-11-14
US20030138493A1 (en) 2003-07-24
JP2002534456A (ja) 2002-10-15
US20040071774A1 (en) 2004-04-15
US6479067B2 (en) 2002-11-12

Similar Documents

Publication Publication Date Title
TR200102012T2 (tr) Yumurtalık kanserinin tedavi yöntemleri, poli (fosfoester) bileşimler ile bunlara ait biyolojik olarak parçalanabilir maddeler.
TR200102801T2 (tr) Solid tümörlerin tedavisine yönelik yöntem ve bileşimler
BRPI0612845A8 (pt) composto, formulação farmacêutica, métodos para tratar câncer e para sintetizar um composto de fórmula alq-dispasador
EP1015008A4 (en) COMPOUNDS AND COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS
TR200002299T2 (tr) Epotilon kompozisyonları.
DE69925276D1 (de) Stoffe und zusammensetzungen für die verabreichung aktiver substanzen
GEP20043375B (en) APRIL-Receptor (BCMA) and Use Thereof
WO2004050033A3 (en) Method of treating cancers
CA2247848A1 (en) Nitric oxide donors capable of reducing toxicity from drugs
CY1105788T1 (el) Χρηση του taci σαν παραγοντα καταπολεμησης ογκων
AR023616A1 (es) Preparaciones combinadas que comprenden derivados de antraciclina
WO2008103847A3 (en) Bridged polycyclic compound based compositions for the inhibition and amelioration of disease
BR9908391A (pt) Composição antitumural contendo uma combinação sinergìstica de um derivado de antraciclina com um derivado de camptotecina
BR0206046A (pt) Usos de uma combinação e de sapogenina protopanaxadiol ou sapogenina protopanaxatriol, e, composição farmacêutica
TR200200619T2 (tr) İkame edilmiş fenoksiasetik asitler.
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
TR200101766T2 (tr) Dehidroepiandrosteronun klatratları ve bunlara tekabül eden kompozisyonlar
CY1109541T1 (el) Φαρμακευτικη συνταγοποιηση για την θεραπεια οστεοαρθριτιδας η οποια περιεχει κλοδρονικο οξυ και υαλουρονικο οξυ
TR200001724T2 (tr) 5-HT1F Agonistleri
NZ523606A (en) Pharmaceutical compositions and methods for use
DK1135169T3 (da) Anvendelse af et farmaceutisk præparat indeholdende et anticancermiddel og mindst et peptid.
AU6749401A (en) Use of aloe-emodin in the treatment of neuroectodermal tumors
BRPI0416870A (pt) composições anticáncer sinergìticas
EP1680098A4 (en) DELAYED RELEASE OF POSITIVELY-LOADED PHARMACOLOGICALLY EFFECTIVE MOLECULES FROM A POLYMER-CONTAINING MATRIX WITH POLARIZED OXYGENATOMES
ATE208627T1 (de) Orale zusammensetzungen mit niedrigdosierten zytotoxischen proteinen